Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes (Q59082814)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Filipa Mendes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Tânia S Morais

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ana Isabel Tomaz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Andreia Valente

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

M. Helena Garcia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Joana Coimbra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Isabel Santos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Manuel Bicho

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Fernanda Marques

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

23 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

Journal of Biological Inorganic Chemistry

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

853-867

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

Cellular processing of platinum anticancer drugs

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

New metal complexes as potential therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Platinum drug distribution in cancer cells and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Recent developments in ruthenium anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Subcellular targets of cisplatin cytotoxicity: an integrated view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Antitumour metal compounds: more than theme and variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

New trends for metal complexes with anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

DNA interaction and cytotoxicity studies of new ruthenium(II) cyclopentadienyl derivative complexes containing heteroaromatic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

New water-soluble ruthenium(II) cytotoxic complex: biological activity and cellular distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Biological activity and cellular uptake of [Ru(η5-C5H5)(PPh3)(Me2bpy)][CF3SO3] complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

[RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

The cancer cell's "power plants" as promising therapeutic targets: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Energy metabolism in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Targeting of cancer energy metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Glycolysis in cancer: a potential target for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Lactate: a metabolic key player in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Is cancer a disease of abnormal cellular metabolism? New angles on an old idea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Hypoxia, glucose metabolism and the Warburg's effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Metabolic Targeting of Malignant Tumors: Small-Molecule Inhibitors of Bioenergetic Flux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

3-Bromopyruvate: targets and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Plasma membrane redox activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Putting together a plasma membrane NADH oxidase: a tale of three laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Trans-plasma membrane electron transport in mammals: functional significance in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Control of NADH ferricyanide reductase activity in the human erythrocyte by somatotrophin and insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Reduction of extracellular potassium ferricyanide by transmembrane NADH: (acceptor) oxidoreductase of human erythrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Insulin and high glucose modulation of phosphatase and reductase enzymes in the human erythrocytes: a comparative analysis in normal and diabetic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

An ascorbate-mediated transmembrane-reducing system of the human erythrocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

VDAC1 is a transplasma membrane NADH-ferricyanide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

A highly sensitive colorimetric microplate ferrocyanide assay applied to ascorbate-stimulated transplasma membrane ferricyanide reduction and mitochondrial succinate oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Homocysteine is a potent modulator of plasma membrane electron transport systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Plasma membrane electron transport: a new target for cancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Inhibition of trans-plasma membrane electron transport: a potential anti-leukemic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

New polydentate Ru(III)-Salan complexes: Synthesis, characterization, anti-tumour activity and interaction with human serum proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Synthesis and biological studies of pyrazolyl-diamine Pt(II) complexes containing polyaromatic DNA-binding groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Binding of cis - and trans -Dichlorodiammineplatinum(II) to DNA: Evidence for Unwinding and Shortening of the Double Helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

A role for Na+/H+ exchangers and intracellular pH in regulating vitamin C-driven electron transport across the plasma membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Distinct trans-plasma membrane redox pathways reduce cell-impermeable dyes in HeLa cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Tumor glycolysis as a target for cancer therapy: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00775-014-1120-Y

Transplasma membrane electron transport comes in two flavors.

21 January 2018

1 reference

12 December 2020

On respiratory impairment in cancer cells

1 reference

12 December 2020

Comparison of bathophenanthroline sulfonate and ferene as chromogens in colorimetric measurement of low hepatic iron concentration.

1 reference

12 December 2020

The antitumor drug, cis diamminedichloro-platinum, inhibits trans plasmalemma electron transport in HeLa cells

1 reference

12 December 2020

A QM/MM study of the binding of RAPTA ligands to cathepsin B

1 reference

12 December 2020

Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells

1 reference

12 December 2020

Glycolytic enzyme inhibitors in cancer treatment

1 reference

12 December 2020

Activation of a NADH dehydrogenase in the human erythrocyte by beta-adrenergic agonists: possible involvement of a G protein in enzyme activation

1 reference

12 December 2020

A SENSITIVE AND SIMPLE METHOD FOR DETERMINATION OF FERROCYANIDE

1 reference

12 December 2020

Cytoskeleton structure and dynamic behaviour: quick excursus from basic molecular mechanisms to some implications in cancer chemotherapy

1 reference

12 December 2020

10.1007/S00775-014-1120-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562604%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference